TY - JOUR AB - Hepatocellular carcinoma (HCC) is the most common form of adult liver cancer and accounts for approximately 90% of all cases of primary liver cancer annually. Rhotekin (RTKN), which functions as a cancer promoter, can be frequently detected in many human cancers, including gastric cancer, colorectal carcinoma and bladder carcinoma. The aim of this study was to investigate the role of RTKN in HCC. Using HCC cells and tissues from patients with liver cancer, we demonstrated that RTKN was significantly increased in HCC. To examine the effect of RTKN on HCC, RTKN overexpressed or silenced HepG2 and Hep3B cells were constructed. Cell proliferation and apoptosis were measured by RT-PCR and flow cytometry. The results showed that RTKN can function as an oncogene and promote the proliferation, while inhibiting apoptosis, of HepG2 and Hep3B cells. Furthermore, we identified that RTKN is a direct gene target of miR-152. miR-152 can reverse the growth promoting effect of RTKN on HCC cells through G2/M phase arrest and nuclear factor-κB (NF-κB) signal inhibition. In conclusion, our research identified that miRNA-152 can inhibit tumor cell growth by targeting RTKN in HCC. AD - Department of Radiotherapy, Tangdu Hospital, The 4th Military Medical University, Xi'an, Shaanxi 710038, P.R. China AU - Zhou,Jiejing AU - Zhang,Yanjun AU - Qi,Yuhong AU - Yu,Dequan AU - Shao,Qiuju AU - Liang,Jun DA - 2017/02/01 DO - 10.3892/or.2016.5290 EP - 1234 IS - 2 JO - Oncol Rep KW - microRNA-152 rhotekin hepatocellular carcinoma NF-κB PY - 2017 SN - 1021-335X 1791-2431 SP - 1227 ST - MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma T2 - Oncology Reports TI - MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma UR - https://doi.org/10.3892/or.2016.5290 VL - 37 ER -